ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Sutro Biopharma, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -19.58
- NET SALES(Q) At USD 9.84 MM has Fallen at -84.57%
- PRE-TAX PROFIT(Q) At USD -38.33 MM has Fallen at -655.12%
- NET PROFIT(Q) At USD -38.33 MM has Fallen at -653.69%
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 89.88%, its profits have risen by 41.7%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Sutro Biopharma, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Sutro Biopharma, Inc.
89.88%
0.28
1111.03%
S&P 500
15.76%
1.20
13.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
19.12%
EBIT Growth (5y)
-12.16%
EBIT to Interest (avg)
-19.58
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.97
Sales to Capital Employed (avg)
0.57
Tax Ratio
0.97%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
61.65%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-3.06
EV to EBIT
-4.67
EV to EBITDA
-5.03
EV to Capital Employed
-10.54
EV to Sales
4.79
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
NET PROFIT(HY)
Higher at USD -76.77 MM
-23What is not working for the Company
NET SALES(Q)
At USD 9.84 MM has Fallen at -84.57%
PRE-TAX PROFIT(Q)
At USD -38.33 MM has Fallen at -655.12%
NET PROFIT(Q)
At USD -38.33 MM has Fallen at -653.69%
RAW MATERIAL COST(Y)
Grown by 10.26% (YoY
CASH AND EQV(HY)
Lowest at USD 366.9 MM
Here's what is not working for Sutro Biopharma, Inc.
Net Sales
At USD 9.84 MM has Fallen at -84.57%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -38.33 MM has Fallen at -655.12%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -38.33 MM has Fallen at -653.69%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Cash and Eqv
Lowest at USD 366.9 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 10.26% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
